Ergocalciferol (Vitamin D2)
- Atc Codes:A11CC01
- CAS Codes:50-14-6
- PHARMGKB ID:50-14-6
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Toxicological Effects
- Genes that may be involved
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Finland: Devitol, Jekovit; France: Sterogyl, Uvesterol D; Greece: Ostelin, Sterogyl, Vitaminol; Hungary: Neogranormon; Italy: Ostelin, Vit. D2; Luxembourg: Sterogyl; Slovakia: Calciferol, Infadin, Vitamin D; UK: Ergocalciferol.
North America
Canada: Drisdol; USA: Drisdol, Vitamin D.
Latin America
Argentina: Ostelin, Raquiferol, Tanvimil D.
Drug combinations
Ergocalciferol: Ascorbic Acid (Vitamin C); Benzalkonium; Benzocaine; Biotin (Vitamin B~7~); Boric Acid; Calcium; Cobalt; Cobamamide; Cod Liver Oil; Cyanocobalamin (Vitamin B~12~); Cyproheptadine; Ferrous Fumarate; Ferrous Sulfate; Fish Liver; Fluoride; Folic Acid (Vitamin B~9~); Ginseng; Iron; Lanolin; Magnesium; Manganese; Molybdenum; Neomycin; Niacin (Vitamin B~3~); Niacinamide; Pantothenic Acid (Vitamin B~5~); Phosphorus; Phytomenadione (Vitamin K~1~); Pollen; Potassium; Pyridoxine (Vitamin B~6~); Retinol (Vitamin A); Riboflavin (Vitamin B~2~); Rutoside; Saccharomyces cerevisiae; Talc; Thiamine (Vitamin B~1~); Tocopherol (Vitamin E); Zinc
Chemistry
Ergocalciferol: C~28~H~44~O. Mw: 396.65. 9,10-Secoergosta-5, 7,10(19), 22-tetraen-3-ol, (3β,5Z,7E,22E). CAS-50-14-6.
Pharmacologic Category
Vitamins; Vitamin D. (ATC-Code: A11CC01).
Mechanism of action
Ergocalciferol increases intestinal absorption of calcium and phosphate and elevates serum calcium and phosphate concentrations sufficiently to permit bone mineralization. Also promotes calcium reabsorption by the kidneys. Activated form of ergocalciferol may have a negative feedback effect on PTH production.
Therapeutic use
Treatment of refractory rickets, hypophosphatemia, hypoparathyroidism. Dietary supplement.
Pregnancy and lactiation implications
Abnormalities observed in animal studies with maternal doses causing hypervitaminosis D. Caution if used in nursing women. Do not administer large doses of vitamin D analogs.
Unlabeled use
Prevention and treatment of vitamin D deficiency in chronic kidney disease.
Contraindications
Hypersensitivity to ergocalciferol or any component of the formulation. Hypercalcemia. Malabsorption syndrome. Hypervitaminosis D or abnormal sensitivity to toxic effects of vitamin D.
Warnings and precautions
Caution in cardiovascular disease, renal impairment, renal stones, arteriosclerosis, or diseases which impair vitamin D metabolism. Hypercalcemia might occur due to hypervitaminosis D. Acute hypercalcemia may increase risk of cardiac arrhythmias and seizures, and result in cardiac arrhythmias in presence of cardiac glycosides. Calcium supplementation is required. Range between therapeutic and toxic doses is narrow in vitamin D-resistant rickets. Effects of vitamin D can last ≥2 months after therapy is discontinued. May contain tartrazine (allergic reactions).